Immunotherapy
ImmunotherapyLymphoma
By Phoebe Starr
This article discusses findings from a clinical trial showing that Keytruda prolongs the time without disease progression in patients with relapsed or refractory classical Hodgkin lymphoma compared with the current standard of therapy.
FDA Approvals, News & UpdatesLiver CancerImmunotherapy
In May 2020, the FDA approved the combination of 2 immunotherapies for patients with metastatic hepatocellular carcinoma (liver cancer) who have not received systemic therapy and cannot be treated by surgery.
Esophageal CancerFDA Approvals, News & UpdatesImmunotherapy
In June 2020, the FDA approved a new indication for Opdivo, a PD-1 inhibitor, for the treatment of patients with unresectable advanced, recurrent, or metastatic esophageal squamous-cell carcinoma, after the use of chemotherapy.
Immunotherapy
Immunotherapy is offering exciting new treatments for many types of cancer. It works by revving up the immune system and can have various side effects in different patients.
Breast CancerImmunotherapy
Recently, Tecentriq became the first immunotherapy to be approved for the treatment of patients with metastatic triple-negative breast cancer, a particularly difficult type of breast cancer.
Breast CancerImmunotherapy
Triple-negative breast cancer is an aggressive type of cancer that usually has a high rate of disease recurrence (returning) within the first 5 years after diagnosis.
Immunotherapy
The immune system attacks foreign substances by making large numbers of antibodies. These are proteins that attach to a specific protein on the cell called an antigen.
